Patents Assigned to Olema Pharmaceuticals, Inc.
-
Patent number: 11672785Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.Type: GrantFiled: December 6, 2021Date of Patent: June 13, 2023Assignee: Olema Pharmaceuticals, Inc.Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
-
Publication number: 20230109666Abstract: Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. In some embodiments, estrogen receptor antagonists provided herein are tetrahydro pyrido[3,4-b]indole compounds. In some embodiments, provided antagonists are complete estrogen receptor antagonists.Type: ApplicationFiled: July 6, 2020Publication date: April 6, 2023Applicant: Olema Pharmaceuticals, Inc.Inventors: Cyrus L. Harmon, Peter J. Kushner, David C. Myles, Leslie Hodges Gallagher, Richard Sun
-
Patent number: 11229630Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.Type: GrantFiled: April 17, 2020Date of Patent: January 25, 2022Assignee: Olema Pharmaceuticals, Inc.Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
-
Patent number: 10624878Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.Type: GrantFiled: April 23, 2019Date of Patent: April 21, 2020Assignee: Olema Pharmaceuticals, Inc.Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
-
Patent number: 10292971Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.Type: GrantFiled: September 29, 2016Date of Patent: May 21, 2019Assignee: Olema Pharmaceuticals, Inc.Inventors: David C. Myles, Peter J. Kushner, Cyrus L. Harmon
-
Publication number: 20150197506Abstract: Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.Type: ApplicationFiled: March 17, 2015Publication date: July 16, 2015Applicant: OLEMA PHARMACEUTICALS, INC.Inventors: Peter J. Kushner, David C. Myles, Cyrus L. Harmon, Leslie Carol Hodges Gallagher
-
Patent number: 9018244Abstract: Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.Type: GrantFiled: December 17, 2012Date of Patent: April 28, 2015Assignee: Olema Pharmaceuticals, Inc.Inventors: Peter J. Kushner, David C. Myles, Cyrus L. Harmon, Leslie Carol Hodges Gallagher
-
Publication number: 20130178445Abstract: Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.Type: ApplicationFiled: December 17, 2012Publication date: July 11, 2013Applicant: OLEMA PHARMACEUTICALS, INC.Inventor: OLEMA PHARMACEUTICALS, INC.
-
Patent number: 8063249Abstract: The present invention is directed to compounds, compositions thereof, and the use of the compounds and compositions for the treatment and prevention of breast cancer. In one embodiment, the present invention relates to the use of a substituted triphenyl butene or prodrug thereof for the treatment of breast cancer in mono-therapy or in combination therapy, or for a reduction in the recurrence rate of previously-treated breast cancer.Type: GrantFiled: April 23, 2009Date of Patent: November 22, 2011Assignee: Olema Pharmaceuticals, Inc.Inventors: Peter Kushner, Cyrus Harmon, David Myles